SAN FRANCISCO, Sept. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Wednesday, September 3, to discuss partnering plans for Dimebon.
Teleconference/Webcast Details
To participate in the live call on Wednesday, September 3, at 8:30 a.m. Eastern Time by telephone, please dial 877-681-3375 from the U.S. or +1-719-325-4933 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company’s website for 30 days.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company’s current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer’s disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington’s disease based on the positive results seen in its Phase 2 trial. For more information, please visit us at http://www.medivation.com.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101; or Daryl Messinger of WeissComm Partners, +1-415-999-2361,
for Medivation, Inc.
Web site: http://www.medivation.com/
